不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤患者 4 周期 R-CHOP 样方案治疗后外周血 NK 细胞绝对计数的预后影响
英文原题：Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.
查看英文原题
Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自然杀伤（NK）细胞作为淋巴细胞亚群，是抗肿瘤免疫应答及临床结局的一线防御力量。本研究旨在调查弥漫大B细胞淋巴瘤（DLBCL）患者接受4个周期利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗后，外周血NK细胞绝对计数（NKCC4）的预后影响。研究纳入2018年1月至2022年9月接受R-CHOP治疗的261例DLBCL患者。研究期间死亡者的NKCC4低于存活者。与NKCC4≥135个细胞/μL者相比，NKCC4<135个细胞/μL对总生存期和无进展生存期（PFS）均有显著不利影响（分别p<0.0001及p<0.0004）。
此外，在生发中心B细胞样（GCB）亚型或国际预后指数（IPI）高的DLBCL患者中，NKCC4<135个细胞/μL组的OS和PFS进一步呈协同降低。
总之，本研究提示治疗第4周期后的NK细胞计数是临床实践中有价值的指标，并为联合R-CHOP改善DLBCL患者结局提供了参考。
展开英文摘要原文
As a subtype of lymphocyte, natural killer (NK) cell is the first line of defense that shows a strong function in tumor immunotherapy response and clinical outcomes. The current study aims to investigate the prognostic influence of peripheral blood absolute NK cell count after four cycles of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment (NKCC4) in diffuse large B cell lymphoma (DLBCL) patients.
A total of 261 DLBCL patients treated with R-CHOP from January 2018 to September 2022 were enrolled. The low NKCC4 was observed in patients who died during the study period compared with survival individuals. A NKCC4 < 135 cells/ l had a remarkable negative influence in overall survival and progression-free survival (PFS) compared to a NKCC4 135 cells/ l (p < 0. 0001 and p < 0. 0004, respectively).
In addition, the OS and PFS were synergistically lower in a NKCC4 < 135 cells/ l group among DLBCL patients with GCB type or high IPI.
In conclusion, this study indicates NCKK4 as a valuable marker in clinical practice and provides an insight for combination treatment of R-CHOP to improve outcomes of DLBCL patients.
论文信息
- 作者
- Huo Z、Chen F、Zhao J、Liu P、Chao Z、Liu K、Zhou J、Zhou D
- 第一作者单位
- Department of Hematology, Central Hospital of Xiangtan, Xiangtan, 411100, China.China
- 通讯作者单位
- Department of Hematology, Central Hospital of Xiangtan, Xiangtan, 411100, China. 1840059465@qq.com.China
- 期刊
- Clinical and experimental medicine2023 Dec
- 原文标识
- PubMed 37938466 · DOI 10.1007/s10238-023-01249-0
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →